CTX — Crescita Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$8.50m
- CA$0.37m
- CA$17.52m
- 77
- 83
- 12
- 59
Annual balance sheet for Crescita Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 9.27 | 14.3 | 11.3 | 8.24 | 9.38 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.58 | 1.36 | 3.75 | 6.24 | 2.77 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 15.9 | 19.4 | 20.1 | 20.5 | 18.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.18 | 0.786 | 2.58 | 2.31 | 1.85 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 26.8 | 26.8 | 28.9 | 28.5 | 24.6 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.34 | 4.62 | 6.72 | 6.06 | 4.86 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.73 | 5.7 | 8.4 | 7.39 | 5.78 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 21.1 | 21.1 | 20.5 | 21.1 | 18.8 |
| Total Liabilities & Shareholders' Equity | 26.8 | 26.8 | 28.9 | 28.5 | 24.6 |
| Total Common Shares Outstanding |